Pharmacokinetics
| . | Dose level . | ||
|---|---|---|---|
| 10 μg/kg . | 20 μg/kg . | 30 μg/kg . | |
| Mean total daily dose, μg | 720 | 1353 | 1833 |
| Cmax, pg/mL | 1048.5 | 1656.8 | 1341 |
| Tmax, h | 2 | 6 | 6 |
| AUC total, pg/mL per min | 795 574 | 4 645 770* | 3 207 650 |
| t1/2, h | 8.7 | 40.2* | 34.6 |
| Clearance, mL/min | 905 | 259* | 571 |
| . | Dose level . | ||
|---|---|---|---|
| 10 μg/kg . | 20 μg/kg . | 30 μg/kg . | |
| Mean total daily dose, μg | 720 | 1353 | 1833 |
| Cmax, pg/mL | 1048.5 | 1656.8 | 1341 |
| Tmax, h | 2 | 6 | 6 |
| AUC total, pg/mL per min | 795 574 | 4 645 770* | 3 207 650 |
| t1/2, h | 8.7 | 40.2* | 34.6 |
| Clearance, mL/min | 905 | 259* | 571 |
In the 20-μg/kg cohort, PK parameters could only be calculated for 3 of 6 patients treated. IL-7 plasma concentrations at 24 hours were still elevated in 3 patients, and there was no available sample until day 14 to document IL-7 decrease.